Statins: 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors demonstrate anti-atherosclerotic character due to their antioxidant capacity

Applied Biochemistry and Biotechnology
Mohan-Kumari H PuttananjaiahShradha Keni

Abstract

Atherosclerosis is a chronic inflammatory disease of multiple etiologies. It is associated with the accumulation of oxidized lipids in arterial lesions leading to coronary heart disease. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (commonly known as statins) are widely used in cardiovascular disease prevention to lower the cholesterol. The antioxidant activity of HMG-CoA reductase inhibitors was studied by lipid peroxidation inhibition assay, DPPH, and hydroxyl radical scavenging-activity methods. The lovastatin (93%) and simvastatin (96%) showed significant action of lipid peroxidation inhibition compared to other HMG-CoA reductase inhibitors. The DPPH radical and hydroxyl radical scavenging activity of simvastatin was 38% and 33%, respectively. The oxidative modification of serum lipid due to reactive oxygen species causes atherosclerosis. This study revealed the importance of lovastatin and simvastatin to prevent oxidative stress-related cardiovascular diseases.

References

Apr 6, 1989·The New England Journal of Medicine·D SteinbergJ L Witztum
Jan 1, 1982·Annals of the New York Academy of Sciences·W A Pryor
Jan 1, 1997·Free Radical Biology & Medicine·R Meneghini
Jun 2, 1998·Drug Metabolism Reviews·E R Stadtman, B S Berlett
Oct 29, 1999·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·J Chaudière, R Ferrari-Iliou
Dec 20, 1999·Chemical & Pharmaceutical Bulletin·K SuzumuraH Narita
Mar 24, 2000·Free Radical Research·J SastreJ Viña
May 12, 2001·Science·E S Istvan, J Deisenhofer
Nov 21, 2001·The Journal of Clinical Investigation·M TakemotoJ K Liao
Jan 5, 2002·Journal of Agricultural and Food Chemistry·R P SinghG K Jayaprakasha
Aug 8, 2002·The Journal of Nutritional Biochemistry·D ButterfieldVittorio Calabrese
Apr 26, 2003·Atherosclerosis. Supplements·Eva Istvan
Jan 26, 2007·Clinical and Experimental Pharmacology & Physiology·Andrew J Brown
Nov 30, 2007·Journal of Applied Microbiology·M A DhaleG Vijayalakshmi

❮ Previous
Next ❯

Citations

Sep 30, 2015·Progress in Lipid Research·Gianna FerrettiAmirhossein Sahebkar
May 20, 2014·Evidence-based Complementary and Alternative Medicine : ECAM·Janet P-C WongTeng-Jin Khoo
Oct 13, 2016·The Journal of Antibiotics·Arnold L Demain, Evan Martens
Aug 6, 2013·Applied Biochemistry and Biotechnology·Sudheer Kumar Singh, Ashok Pandey
Sep 17, 2014·EMBO Reports·Mauricio G MartínCarlos G Dotti
Dec 31, 2011·Molecular and Cellular Biochemistry·Nathan VandjelovicYunbo Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Related Papers

Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Für Toxikologische Pathologie
Yi AnXiaoxu Zhou
Progress in Neurobiology
Peter J van der MostUlrich L M Eisel
Journal of the American College of Cardiology
Rainer Schulz
© 2021 Meta ULC. All rights reserved